1-2 of 2
Ping Jiang
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204)

Clinical Trials & Observations
Tycel J. Phillips, Abraham Avigdor, Ronit Gurion, Caterina Patti, Paolo Corradini, Monica Tani, Amitkumar Mehta, Izidore S. Lossos, Pier Luigi Zinzani, Catherine Thieblemont, Wojciech Jurczak, Fred Zheng, Erica Rappold, Wanying Zhao, Ping Jiang, Peter Johnson
Journal: Blood Advances
Blood Adv (2024) 8 (4): 867–877.
https://doi.org/10.1182/bloodadvances.2023010648
Published: 2024
Includes: Supplemental data
Journal Articles

CLT030, a leukemic stem cell–targeting CLL1 antibody-drug conjugate for treatment of acute myeloid leukemia

Ying-Ping Jiang, Bob Y. Liu, Quan Zheng, Swapna Panuganti, Ruoying Chen, Jianyu Zhu, Madhavi Mishra, Jianqing Huang, Trang Dao-Pick, Sharmili Roy, XiaoXian Zhao, Jeffrey Lin, Gautam Banik, Eric D. Hsi, Ramkumar Mandalam, Jagath R. Junutula
Journal: Blood Advances
Blood Adv (2018) 2 (14): 1738–1749.
https://doi.org/10.1182/bloodadvances.2018020107
Published: 2018
Includes: Supplemental data